NEW YORK, NY / ACCESSWIRE / September 17, 2021 / The Law Offices of Vincent Wong announce that class actions have commenced on behalf of certain shareholders in the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff. There will be no obligation or cost to you.
Iterum Therapeutics Plc (NASDAQ: ITRM)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/iterum-therapeutics-plc-loss-submission-form?prid=19640&wire=1
Lead Plaintiff Deadline: October 4, 2021
Class Period: November 30, 2020 - July 23, 2021
Allegations against ITRM include that: (i) the sulopenem New Drug Application ("NDA") lacked sufficient data to support approval for the treatment of adult women with urinary tract infections caused by designated susceptible microorganisms proven or strongly suspected to be nonsusceptible to a quinolone; (ii) accordingly, it was unlikely that the Food and Drug Administration would approve the sulopenem NDA in its current form; (iii) Defendants downplayed the severity of issues and deficiencies associated with the sulopenem NDA; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.
ATI Physical Therapy, Inc. f/k/a Fortress Value Acquisition Corp. II (NYSE: ATIP)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/ati-physical-therapy-inc-f-k-a-fortress-value-acquisition-corp-ii-loss-submission-form?prid=19640&wire=1
Lead Plaintiff Deadline: October 15, 2021
This lawsuit is on behalf of investors who: (a) purchased or otherwise acquired ATI securities between April 1, 2021 and July 23, 2021, inclusive and/or (b) held FVAC Class A common stock as of May 24, 2021 and were eligible to vote at FVAC's June 15, 2021 special meeting.
Allegations against ATIP include that: (1) ATI was experiencing attrition among its physical therapists; (2) ATI faced increasing competition for clinicians in the labor market; (3) as a result of the foregoing, the Company faced difficulties retaining therapists and incurred increased labor costs; (4) as a result of the labor shortage, the Company would open fewer new clinics; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.
Cassava Sciences, Inc. (NASDAQ: SAVA)
If you suffered a loss, contact us at: https://www.wongesq.com/pslra-1/cassava-sciences-inc-loss-submission-form?prid=19640&wire=1
Lead Plaintiff Deadline: October 26, 2021
Class Period: February 2, 2021 - August 24, 2021
Allegations against SAVA include that: (a) the quality and integrity of the scientific data supporting Cassava's claims for simufilam's, a small molecule drug designed to treat Alzheimer's disease, efficacy had been overstated; (b) the scientific data supporting Cassava's claims for simufilam's efficacy were biased; and (c) as a result of the foregoing, Defendants' positive statements during the Class Period about the Company's business metrics and financial prospects and the likelihood of Food and Drug Administration approval were false and misleading and/or lacked a reasonable basis.
To learn more contact Vincent Wong, Esq. either via email vw@wongesq.com or by telephone at 212.425.1140.
Vincent Wong, Esq. is an experienced attorney who has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:
Vincent Wong, Esq.
39 East Broadway
Suite 304
New York, NY 10002
Tel. 212.425.1140
Fax. 866.699.3880
E-Mail: vw@wongesq.com
SOURCE: The Law Offices of Vincent Wong
View source version on accesswire.com:
https://www.accesswire.com/664471/SHAREHOLDER-ALERT-ITRM-ATIP-SAVA-The-Law-Offices-of-Vincent-Wong-Reminds-Investors-of-Important-Class-Action-Deadlines
